Transcript powerpoint file

USAID Neglected Tropical Diseases Program
WHO 17 NTDs by Strategic Interventions
WHO 17 Neglected Tropical Diseases (NTDs)
by Strategic Interventions
PC
Preventive Chemotherapy
“an intervention that allows the regular
and coordinated administration of qualityassured, safe, single-dose medicines on a
large scale”
IDM
Intensified Disease Management
“directed at NTDs for which simple tools
and treatments are not yet available”
Specific Intervention
Approaches
“other measures to support these
interventions involve control of vectors and
their intermediates hosts, veterinary public
health, WASH and capacity building”
•
•
•
•
•
•
Lymphatic filariasis
Onchocerciasis
Schistosomiasis
Trachoma
Soil Transmitted Helminths
Foodborne trematodes
•
•
•
•
•
•
Buruli Ulcer
Chagas disease
Cysticercosis
Dengue fever
Echinococcosis
Human African
trypanosomiasis
• Leprosy
• V. Leishmaniasis
• Yaws
• Dengue
• Guinea-Worm
• Rabies
London
Declaration
10 NTDs
•
•
•
•
•
Lymphatic filariasis
Onchocerciasis
Schistosomiasis
Trachoma
Soil Transmitted
Helminths
• Chagas disease
• Human African
trypanosomiasis
• Leprosy
• V. Leishmaniasis
• Guinea worm
2
USAID
5 NTDs
•
•
•
•
•
Lymphatic filariasis
Onchocerciasis
Schistosomiasis
Trachoma
Soil Transmitted
Helminths
USAID Targeted Diseases
Lymphatic
Filariasis
Onchocerciasis
Schistosomiasis
Soil-transmitted
Helminths
Trachoma
Hygiene
Hands
Flies
Mosquitoes
120 Million
Infected
1.2 Billion at risk
Black flies
37 Million Infected
0.4 Billion at risk
Snails
200 Million Infected
0.7 Billion at risk
Direct fecal
contamination
800 Million
Infected
1.2 Billion at risk
3
84 Million
Infected
1.2 Billion at
risk
Integrated Approach
LF
Albendazole
Ivermectin
DEC
Oncho
Ivermectin
Schisto
STH
Trachoma
Surgery,
Praziquantel Albendazole
Antibiotic
Mebendazole (Azithromycin),
Face washing,
Environmental
control
(SAFE)
Core Program Investments
• Disease Mapping – defining the disease burden and
drug package
• Mass Drug Administration – Integrated community wide
treatment for the PCT diseases
• Monitoring & Evaluation – program performance
• Surveillance/Impact assessment – monitoring and
documenting disease specific progress towards control
and elimination
Strategic Investments
Targeted investments to fill gaps that hinder USAID
supported countries from achieving the elimination and
control targets and contribute to the global evidence
Base.
• Morbidity Management & Disability Prevention
• Operations Research
• New Drug Development
• Supply Chain Management & Drug Quality
Why Treat NTDs?
Reduced stunting and anemia
Ancillary treatment of
other diseases (scabies,
trematodes, yaws, etc.)
Reduced poverty and
increased economic
opportunity and
agricultural output
Reduced
NTD
Burden
Increased productivity
and quality of life
Improved school
attendance and cognitive
development
Reduced vulnerability to other
disease (HIV, Cancer, etc)
31 Countries supported by USAID
Haiti
REGIONAL
Colombia
Ecuador
Guatemala
Mexico
Venezuela
Brazil
= regional program
= country programs
Benin
Burkina Faso
Cameroon
Côte d'Ivoire
DR Congo
Ethiopia
Ghana
Guinea
Mali
Mozambique
Niger
Nigeria
Senegal
Sierra Leone
Tanzania
Togo
Uganda
Bangladesh
Cambodia
Indonesia
Laos
Nepal
Philippines
Vietnam
Progress towards 2020 NTD Goals
DISEASES
WHO
2020 Goal
Number
USAID Supported
Countries
Number
USAID Supported Countries
on track to meet WHO 2020
Goal
USAID PRIORITY DISEASES
Lymphatic Filariasis
Elimination
26
17
Trachoma
Elimination
17
12
Onchocerciasis Americas
By 2018
Elimination
6
6
Onchocerciasis Africa
Soil Transmitted
Helminths
Schistosomiasis
DISEASES BENEFITTING FROM INTEGRATION
Control
15
Elimination where
possible*
Control
26
Control
19
*New WHO guidelines released 12/2015 which will be used to determine countries on-track for elimination.
13 Control
(# Elimination/TBD)
19
(100% geographical
coverage)
11
(100% geographical
coverage)
9
Number of Individuals Treated and Treatments
Provided with USAID Support
Millions
Total Individuals treated
350
Total Treatments provided
287
300
244
250
242
240
208
200
161
150
140
131
93
100
58
37
50
16
55
105
121
117
FY 2013
FY 2014
68
28
0
FY 2007
FY 2008
FY 2009
FY 2010
FY 2011
FY 2012
FY2015*
*Data outstanding
Millions
Number of Individuals Treated and Treatments
Provided with USAID Support
1,600
1496.1
1,400
1321.1
1,200
1080.9
1,000
838.7
Total Individuals treated
Total Treatments provided
800
691.3
594.4
Cumulative Persons treated
Cumulative Treatments provided
603.5
600
486.7
386.2
366.2
400
260.7
225.5
167.3
200
94.9
36.8
16.3
99.0
44.0
*Data outstanding
0
FY 2007
FY 2008
FY 2009
FY 2010
FY 2011
FY 2012
FY 2013
FY 2014
FY2015*
Leverage of Drug Donations - $1:$26
$8.87 billion in drugs
have been donated
to countries
supported by USAID
Persons Living in Districts Where Criteria for
Stopping MDA Have Been Achieved
140
127.5
120
Lymphatic
Filariasis
100
Millions
92.4
80
Trachoma
60
54.32
52.4
45.45
40
32
27
35.76
20
7.7
0
2011
2012
Data for FY15 is still being compiled
2013
2014
2015
13
Progress towards 2020 Goal:
Stop MDA for LF and Trachoma
(%) Persons living in districts where
criteria for stopping MDA have been
achieved for LF
(%) Persons living in districts where
criteria for stopping district-level MDA
have been achieved for trachoma
100%
90%
90%
80%
80%
70%
70%
60%
60%
(%)
100%
50%
50%
40%
40%
30%
30%
20%
20%
10%
10%
0%
0%
Countries
Countries
14
Improving SURGICAL QUALITY
Hydrocele Surgery (LF)
Trichiasis Surgery (Trachoma)
Global Capacity Building
1,517,430
78
People Trained
Countries
(2012—present)
where global NTD
trainings have reached
individuals
Types of training: global, regional, national, sub-national
Thank You!
Emily Wainwright, MPH, RD
Acting Division Chief
USAID NTD Program
[email protected]
Rob Henry, MPH
Senior Public Health Advisor
USAID NTD Program
[email protected]
17